A lipidated peptide with mitochondrial membrane localization in human A549 lung cells: from enhanced cell-penetrating properties to biological activity mechanism
X Zhang, A Angelova, W Sun, F Zhang… - ACS Applied Bio …, 2021 - ACS Publications
Here, a lipidated peptide Pal-pHK-pKV with self-assembly properties and the ability to
provoke the disruption of the mitochondrial voltage-dependent anion channel-1 protein …
provoke the disruption of the mitochondrial voltage-dependent anion channel-1 protein …
Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
JY Wu, JY Shih - OncoTargets and therapy, 2016 - Taylor & Francis
Background Clinical features of epidermal growth factor receptor (EGFR) mutations: L858R,
deletions in exon 19, T790M, insertions in exon 20, G719X, and L861X in non-small-cell …
deletions in exon 19, T790M, insertions in exon 20, G719X, and L861X in non-small-cell …
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells
HC Chiu, DL Chou, CT Huang, WH Lin, TW Lien… - Biochemical …, 2011 - Elsevier
Epidermal growth factor receptor (EGFR) is a proven therapeutic target to treat a small
subset of non small cell lung cancer (NSCLC) harboring activating mutations within the …
subset of non small cell lung cancer (NSCLC) harboring activating mutations within the …
Identification of microRNAs involved in gefitinib resistance of non‑small‑cell lung cancer through the insulin‑like growth factor receptor 1 signaling pathway
W Ma, Y Kang, L Ning, J Tan… - Experimental and …, 2017 - spandidos-publications.com
Multiple clinical and experimental studies have suggested that epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR‑TKIs) may be effective at treating advanced non …
receptor tyrosine kinase inhibitors (EGFR‑TKIs) may be effective at treating advanced non …
Non-small cell lung carcinoma: An overview on targeted therapy
AV Nascimento, H Bousbaa, D Ferreira… - Current drug …, 2015 - ingentaconnect.com
Non-small cell lung cancer (NSCLC) represents close to 90% of all lung cancers. When
diagnosed, most cases are on an advanced and inoperable stage, with limited therapeutic …
diagnosed, most cases are on an advanced and inoperable stage, with limited therapeutic …
Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non‑small cell lung cancer: A network meta‑analysis
Y Liu, Y Zhang, G Feng, Q Niu… - Experimental and …, 2017 - spandidos-publications.com
The present network meta‑analysis aimed to compare the effectiveness and adverse effects
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …
[图书][B] Lung cancer and lung injury: the dual role of ceramide
T Goldkorn, S Chung, S Filosto - 2013 - Springer
Sphingolipids play key roles in cancer, yet our current understanding of sphingolipid
function in lung cancer is limited to a few key players. The best characterized of these are …
function in lung cancer is limited to a few key players. The best characterized of these are …
EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
Background Epidermal growth factor receptor (EGFR) mutation-induced drug resistance has
caused great difficulties in the treatment of non-small-cell lung cancer (NSCLC). However …
caused great difficulties in the treatment of non-small-cell lung cancer (NSCLC). However …
Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung
KS Ng, CK Sun, KB Ting, AYT Kun - European Journal of Radiology, 2020 - Elsevier
Purpose The first-line treatment of metastatic lung adenocarcinoma with epidermal growth
factor receptor (EGFR) mutation is tyrosine kinase inhibitor (TKI). This study aimed to …
factor receptor (EGFR) mutation is tyrosine kinase inhibitor (TKI). This study aimed to …
[HTML][HTML] Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation
Y Li, Y Wang, K Niu, X Chen, L Xia, D Lu, R Kong… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Purpose Acquired resistance is a bottleneck that restricts the efficacy of epidermal growth
factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for lung cancer. Ginsenoside Rg3 is an …
factor receptor-tyrosine kinase inhibitor (EGFR-TKI) for lung cancer. Ginsenoside Rg3 is an …